

# National Institute for Health and Care Excellence

Draft for consultation

## Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education

### Supplement A: Methods

*NICE guideline tbc*

*Methods*

*August 2021*

*Draft for Consultation*

*Developed by the National Guideline Alliance hosted by the Royal College of Obstetricians and Gynaecologists*



## **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

## **Copyright**

© NICE, 2021. All rights reserved. Subject to Notice of rights.

ISBN:

# Contents

<b>Development of the guideline</b> .....	<b>5</b>
Remit.....	5
<b>Methods</b> .....	<b>6</b>
Developing the review questions and outcomes .....	6
Searching for evidence .....	8
Scoping search.....	8
Systematic literature search .....	8
Economic systematic literature search .....	8
Reviewing research evidence .....	9
Systematic review process .....	9
Type of studies and inclusion/exclusion criteria .....	10
Methods of combining evidence .....	10
Data synthesis for intervention studies .....	10
Data synthesis for qualitative reviews .....	11
Combining qualitative and quantitative evidence .....	12
Appraising the quality of evidence .....	12
Intervention studies .....	12
Qualitative studies .....	17
Reviewing economic evidence .....	20
Appraising the quality of economic evidence .....	21
Economic modelling .....	21
Cost effectiveness criteria .....	22
Developing recommendations .....	22
Guideline recommendations .....	22
Research recommendations.....	22
Validation process .....	23
Updating the guideline .....	23
Funding .....	23
<b>References</b> .....	<b>24</b>

# 1 Development of the guideline

## 2 Remit

- 3 To see “What this guideline covers” and “What this guideline does not cover” please
- 4 see the guideline scope [Disabled children and young people up to 25 with severe](#)
- 5 [complex needs](#).

# 1 Methods

2 This guideline was developed using the methods described in the [2018 NICE](#)  
3 [guidelines manual](#).

4 Declarations of interest were recorded according to the [NICE conflicts of interest](#)  
5 [policy](#).

## 6 Developing the review questions and outcomes

7 The review questions developed for this guideline were based on the key areas  
8 identified in the [guideline scope](#). They were drafted by the NGA technical team, and  
9 refined and validated by the guideline committee.

10 The review questions were based on the following frameworks:

- 11 • population, intervention, comparator and outcome (PICO) for reviews of  
12 interventions
- 13 • qualitative reviews – using population, phenomenon of interest and context (PICO)

14 Full literature searches, critical appraisals and evidence reviews were completed for  
15 all review questions.

16 The review questions and evidence reviews corresponding to each question (or  
17 group of questions) are summarised below.

18 **Table 1: Summary of review questions and index to evidence reviews**

Evidence review	Review question	Type of review
[A] Views and experiences of service users	What is the experience of disabled children and young people with severe complex needs and their families and carers of joint delivery of health, social care and education services?	Qualitative
[B] Involving children and young people	What are the most effective practices (for example, communication and information management) to enable health, social care and education services to work together to involve disabled children and young people with severe complex needs in understanding, planning and reviewing their care and education?	Intervention
[C] Combined approaches to identifying, assessing & monitoring needs	What are the most effective combined approaches to identifying, assessing and monitoring the health, social care and education needs (including changing needs) of disabled children and young people with severe complex needs	Intervention
[D] Supporting families and carers	What interventions, such as combined support, communication strategies and short breaks, are effective in enabling families and carers to be involved in the planning and delivery of care for disabled children and young people with severe complex needs?	Intervention
[E] Palliative and end of life care	What combined health, social care and education service delivery arrangements can best provide for the needs of disabled children and young people with severe complex	Intervention

Evidence review	Review question	Type of review
	needs on a palliative or advance care plan, and for the needs of their families and carers?	
[F] Supporting participation in education and social activities	What are the most effective ways that health, social care and education services can work together to support disabled children and young people with severe complex needs to participate in and benefit from education and social activities?	Intervention
[G] Promoting inclusion, independence and wellbeing	What are the most effective approaches for health, social care and education services to work together to promote inclusion, independence and wellbeing of disabled children and young people with severe complex needs?	Intervention
[H] Preparation for employment	What are the most effective models of health, social care and education services working together to prepare disabled children and young people with severe complex needs for employment?	Intervention
[I] Suitability and accessibility of environments	What are the most effective practices (for example, environmental assessments and use of equipment such as assistive technology across different contexts) to ensure the suitability and accessibility of the environments in which disabled children and young people with severe complex needs receive health and social care and education?	Intervention
[J] Planning and managing transition from children's to adults' services	What is the impact of including education with combined health and social care support models and frameworks on transition from children's to adults' services for disabled children and young people with severe complex needs?	Intervention
[K] Barriers and facilitators of joined-up care	What are the barriers and facilitators perceived or experienced by users and providers of joined-up care across health, social care, education and other services for disabled children and young people with severe complex needs?	Qualitative
[L] Enabling professionals to meet needs of children and young people	What are the most effective practices (for example, communication and training) to enable health, social care and education professionals to meet the combined health, social care and education needs of disabled children and young people with severe complex needs?	Intervention
[M] Views and experiences of service providers	What is the experience of commissioners and providers of joint working of health, social care and education services for disabled children and young people with severe complex needs?	Qualitative
[N] Commissioning, practice and service delivery models	<ul style="list-style-type: none"> <li>• What are the most effective commissioning and practice models to deliver joined-up health, social care and education services for disabled children and young people with severe complex needs?</li> <li>• What combined service delivery models are most effective in meeting the health, social care and education needs (including changing and evolving needs) of disabled children and young people with severe complex needs?</li> </ul>	Intervention

- 1 The COMET database was searched for core outcome sets relevant to this guideline.
- 2 No core outcome sets were identified and therefore the outcomes were chosen
- 3 based on committee discussions.

- 1 Additional information related to development of the guideline is contained in:
- 2 • Supplement 2 (Economics)
- 3 • Supplement 3 (NGA staff list).

## 4 **Searching for evidence**

### 5 **Scoping search**

6 During the scoping phase, searches were conducted for previous guidelines,  
7 economic evaluations, health technology assessments, systematic reviews,  
8 randomised controlled trials and qualitative research. Searches of websites of  
9 organisations, institutional repositories and internet search engines were also  
10 undertaken for relevant policies and related documents, including grey literature.

### 11 **Systematic literature search**

12 Systematic literature searches were undertaken to identify published evidence  
13 relevant to each review question.

14 Databases were searched using subject headings, free-text terms and, where  
15 appropriate, study type filters. Where possible, searches were limited to retrieve  
16 studies published in English. All the searches were conducted in the following  
17 databases: Medline, Medline-in-Process, Embase, Health Management Information  
18 Consortium (HMIC), Social Policy and Practice, PsycInfo, Emcare, Cochrane Central  
19 Register of Controlled Trials (CCTR), Cochrane Database of Systematic Reviews  
20 (CDSR), Database of Abstracts of Reviews of Effects (DARE), Health Technology  
21 Assessments (HTA), Applied Social Sciences Index and Abstracts (ASSIA), Social  
22 Services Abstracts, Sociological Abstracts, Educational Resources Information  
23 Centre (ERIC), British Education Index, Cumulative Index to Nursing and Allied  
24 Health (CINAHL plus), Social Sciences Citation Index (SSCI), and Social Care  
25 Online. All searches were restricted by date to 2000 onwards, as stated and  
26 explained in the individual review protocols for each review. The webpages of the  
27 following organisations were also checked for relevant publications for each review  
28 question: Kings Fund, National Audit Office, and Audit Commission.

29 Searches were run once for all reviews during development.

30 Details of the search strategies, including the study-design filters used and  
31 databases searched, are provided in Appendix B of each evidence review.

### 32 **Economic systematic literature search**

33 Systematic literature searches were also undertaken to identify published economic  
34 evidence. Databases were searched using subject headings, free-text terms and,  
35 where appropriate, an economic evaluations search filter.

36 A single search, using the population search terms used in the evidence reviews,  
37 was conducted to identify economic evidence in the NHS Economic Evaluation  
38 Database (NHS EED) and Health Technology Assessment (HTA) database. Another  
39 single search, using the population search terms used in the evidence reviews  
40 combined with an economic evaluations search filter, was conducted in Medline,  
41 Medline in Process, Embase, Health Management Information Consortium (HMIC),



1 Social Policy and Practice, PsycInfo, Emcare, Cochrane Central Register of  
2 Controlled Trials (CCTR), Applied Social Sciences Index and Abstracts (ASSIA),  
3 Social Services Abstracts, Sociological Abstracts, Educational Resources Information  
4 Centre (ERIC), British Education Index, Cumulative Index to Nursing and Allied  
5 Health Literature (CINAHL), Social Sciences Citation Index (SSCI) and Social Care  
6 Online. Where possible, searches were limited to studies published in English. All  
7 searches were restricted by date to 2000 onwards, as stated and explained in the  
8 individual review protocols for each review. The webpages of the following  
9 organisations were also checked for relevant economics publications: Kings Fund,  
10 National Audit Office and Audit Commission

11 As with the general literature searches, the economic literature searches were run  
12 once for all reviews during development.

13 Details of the search strategies, including the study-design filter used and databases  
14 searched, are provided in Supplement 2 (Health economics).

## 15 **Quality assurance**

16 Search strategies were quality assured by cross-checking reference lists of relevant  
17 studies, analysing search strategies from published systematic reviews and asking  
18 members of the committee to highlight key studies. The principal search strategies  
19 for each search were also quality assured by a second information scientist using an  
20 adaptation of the PRESS 2015 Guideline Evidence-Based Checklist  
21 (McGowan 2016). In addition, all publications highlighted by stakeholders at the time  
22 of the consultation on the draft scope were considered for inclusion.

## 23 **Reviewing research evidence**

### 24 **Systematic review process**

25 The evidence was reviewed in accordance with the following approach.

- 26 • Potentially relevant articles were identified from the search results for each review  
27 question by screening titles and abstracts. Full-text copies of the articles were  
28 then obtained.
- 29 • Full-text articles were reviewed against pre-specified inclusion and exclusion  
30 criteria in the review protocol (see Appendix A of each evidence review).
- 31 • Key information was extracted from each article on study methods and results, in  
32 accordance with factors specified in the review protocol. The information was  
33 presented in a summary table in the corresponding evidence review and in a more  
34 detailed evidence table (see Appendix D of each evidence review).
- 35 • Included studies were critically appraised using an appropriate checklist as  
36 specified in [Developing NICE guidelines: the manual](#). Further detail on appraisal  
37 of the evidence is provided below.
- 38 • Summaries of evidence by outcome were presented in the corresponding  
39 evidence review and discussed by the committee.

40 Review questions, selected as high priorities for economic analysis (and those  
41 selected as medium priorities and where economic analysis could influence  
42 recommendations) and complex review questions were subject to dual screening and

1 study selection through a 10% random sample of articles. Any discrepancies were  
2 resolved by discussion between the first and second reviewers or by reference to a  
3 third (senior) reviewer. For the remaining review questions, internal (NGA) quality  
4 assurance processes included consideration of the outcomes of screening, study  
5 selection and data extraction and the committee reviewed the results of study  
6 selection and data extraction. The review protocol for each question specifies  
7 whether dual screening and study selection was undertaken for that particular  
8 question. Drafts of all evidence reviews were quality assured by a senior reviewer.

## 9 **Type of studies and inclusion/exclusion criteria**

10 Inclusion and exclusion of studies was based on criteria specified in the  
11 corresponding review protocol.

12 Systematic reviews with meta-analyses or meta-syntheses were considered to be the  
13 highest quality evidence that could be selected for inclusion.

14 For intervention reviews, randomised controlled trials (RCTs) were prioritised for  
15 inclusion because they are considered to be the most robust type of study design  
16 that could produce an unbiased estimate of intervention effects. Where there was  
17 limited evidence from RCTs, non-randomised studies (NRS) were considered for  
18 inclusion. Service evaluations, process evaluations and audits were considered for  
19 inclusion in the absence of comparative non-randomised studies.

20 For qualitative reviews, studies using focus groups, structured interviews or semi-  
21 structured interviews were considered for inclusion. Where qualitative evidence was  
22 sought, data from surveys or other types of questionnaire were considered for  
23 inclusion only if they provided data from open-ended questions, but not if they  
24 reported only quantitative data.

25 The committee was consulted about any uncertainty regarding inclusion or exclusion  
26 of studies. A list of excluded studies for each review question, including reasons for  
27 exclusion is presented in Appendix J of the corresponding evidence review.

28 Narrative reviews, posters, letters, editorials, comment articles, unpublished studies  
29 and studies published in languages other than English were excluded. Conference  
30 abstracts were not considered for inclusion because conference abstracts typically  
31 do not have sufficient information to allow for full critical appraisal.

## 32 **Methods of combining evidence**

33 When planning reviews (through preparation of protocols), the following approaches  
34 for data synthesis were discussed and agreed with the committee.

## 35 **Data synthesis for intervention studies**

### 36 ***Pairwise meta-analysis***

37 Meta-analysis to pool results from comparative intervention studies was conducted  
38 where possible using Cochrane Review Manager (RevMan5) software.

39 For dichotomous outcomes, such as mortality, the Mantel–Haenszel method with a  
40 fixed effect model was used to calculate risk ratios (RRs). For all outcomes with zero

1 events in both arms the risk difference was presented. For outcomes in which the  
2 majority of studies had low event rates (<1%), Peto odds ratios (ORs) were  
3 calculated as this method performs well when events are rare (Bradburn 2007).

4 For continuous outcomes, measures of central tendency (mean) and variation  
5 (standard deviation; SD) are required for meta-analysis. Data for continuous  
6 outcomes, such as quality of life, were meta-analysed using an inverse-variance  
7 method for pooling weighted mean differences (WMDs). Where SDs were not  
8 reported for each intervention group, the standard error (SE) of the mean difference  
9 was calculated from other reported statistics (p values or 95% confidence intervals;  
10 CIs) and then meta-analysis was conducted as described above.

11 If a study reported only the summary statistic and 95% CI the generic-inverse  
12 variance method was used to enter data into RevMan5. If the control event rate was  
13 reported this was used to generate the absolute risk difference in GRADEpro. If  
14 multivariable analysis was used to derive the summary statistic but no adjusted  
15 control event rate was reported, no absolute risk difference was calculated.

16 When evidence was based on studies that reported descriptive data or medians with  
17 interquartile ranges or p values, this information was included in the corresponding  
18 GRADE tables (see below) without calculating relative or absolute effects.  
19 Consequently, certain aspects of quality assessment such as imprecision of the  
20 effect estimate could not be assessed as per standard methods for this type of  
21 evidence and ratings based on sample size cut-offs were considered instead.

22 For some reviews, evidence was either stratified from the outset or separated into  
23 subgroups when heterogeneity was encountered. The stratifications and potential  
24 subgroups were pre-defined at the protocol stage (see the protocols for each review  
25 for further detail). Where evidence was stratified or subgrouped the committee  
26 considered on a case by case basis if separate recommendations should be made  
27 for distinct groups. Separate recommendations may be made where there is  
28 evidence of a differential effect of interventions in distinct groups. If there is a lack of  
29 evidence in one group, the committee considered, based on their experience,  
30 whether it was reasonable to extrapolate and assume the interventions will have  
31 similar effects in that group compared with others

32 When meta-analysis was undertaken, the results were presented visually using forest  
33 plots generated using RevMan5 (see Appendix E of relevant evidence reviews).

34 When case series were included, descriptive data from the studies were included and  
35 no further analysis was performed.

## 36 **Data synthesis for qualitative reviews**

37 Where possible, a meta-synthesis was conducted to combine evidence from  
38 qualitative studies. Whenever studies identified a qualitative theme relevant to the  
39 protocol, this was extracted and the main characteristics were summarised. When all  
40 themes had been extracted from studies, common concepts were categorised and  
41 tabulated. This included information on how many studies had contributed to each  
42 theme identified by the NGA technical team.

43 Themes from individual studies were integrated into a wider context and, when  
44 possible, overarching categories of themes with sub-themes were identified. Themes  
45 were derived from data presented in individual studies. When themes were extracted

1 from 1 primary study only, theme names used in the guideline mirrored those in the  
2 source study. However, when themes were based on evidence from multiple studies,  
3 the theme names were assigned by the NGA technical team. The names of  
4 overarching categories of themes were also assigned by the NGA technical team.

5 Emerging themes were placed into a thematic map representing the relationship  
6 between themes and overarching categories. The purpose of such a map is to show  
7 relationships between overarching categories and associated themes.

## 8 **Combining qualitative and quantitative evidence**

9 The NGA technical team presented the data from quantitative and qualitative  
10 evidence reviews separately, however for most of the quantitative reviews there was  
11 also relevant qualitative evidence. The committee completed the synthesis of these  
12 mixed data through their discussions of the evidence, referring back to the qualitative  
13 evidence whenever considering the results of quantitative reviews. Where there was  
14 qualitative evidence that supported recommendations made for quantitative reviews,  
15 the supporting evidence is documented in the relevant quantitative review.

## 16 **Appraising the quality of evidence**

### 17 **Intervention studies**

#### 18 *Pairwise meta-analysis*

#### 19 **GRADE methodology for intervention reviews**

20 For intervention reviews, the evidence for outcomes from included RCTs and  
21 comparative non-randomised studies was evaluated and presented using the  
22 Grading of Recommendations Assessment, Development and Evaluation (GRADE)  
23 methodology developed by the international GRADE working group.

24 When GRADE was applied, software developed by the GRADE working group  
25 (GRADEpro) was used to assess the quality of each outcome, taking account of  
26 individual study quality factors and any meta-analysis results. Results were  
27 presented in GRADE profiles (GRADE tables).

28 The selection of outcomes for each review question was agreed during development  
29 of the associated review protocol in discussion with the committee. The evidence for  
30 each outcome was examined separately for the quality elements summarised in  
31 Table 2. Criteria considered in the rating of these elements are discussed below.  
32 Each element was graded using the quality ratings summarised in Table 3. Footnotes  
33 to GRADE tables were used to record reasons for grading a particular quality  
34 element as having a 'serious' or 'very serious' quality issue. The ratings for each  
35 component were combined to obtain an overall assessment of quality for each  
36 outcome as described in Table 4.

37 The initial quality rating was based on the study design: RCTs and NRS assessed by  
38 ROBINS-I start as 'high' quality evidence, other non-randomised studies such as  
39 cross-sectional or before and after studies assessed using the Joanna Briggs  
40 Institute checklist for cross-sectional studies or the EPOC RoB tool, start as 'low'  
41 quality evidence. The rating was then modified according to the assessment of each

1 quality element (Table 2). Each quality element considered to have a ‘serious’ or  
 2 ‘very serious’ quality issue was downgraded by 1 or 2 levels respectively (for  
 3 example, evidence starting as ‘high’ quality was downgraded to ‘moderate’ or ‘low’  
 4 quality). In addition, there was a possibility to upgrade evidence from non-  
 5 randomised studies (provided the evidence for that outcome had not previously been  
 6 downgraded) if there was a large magnitude of effect, a dose–response gradient, or if  
 7 all plausible confounding would reduce a demonstrated effect or suggest a spurious  
 8 effect when results showed no effect.

9 **Table 2: Summary of quality elements in GRADE for intervention reviews**

Quality element	Description
Risk of bias (‘Study limitations’)	This refers to limitations in study design or implementation that reduce the internal validity of the evidence
Inconsistency	This refers to unexplained heterogeneity in the results
Indirectness	This refers to differences in study populations, interventions, comparators or outcomes between the available evidence and inclusion criteria specified in the review protocol
Imprecision	This occurs when a study has few participants or few events of interest, resulting in wide confidence intervals that cross minimally important thresholds
Publication bias	This refers to systematic under- or over-estimation of the underlying benefit or harm resulting from selective publication of study results

10 **Table 3: GRADE quality ratings (by quality element)**

Quality issues	Description
None or not serious	No serious issues with the evidence for the quality element under consideration
Serious	Issues with the evidence sufficient to downgrade by 1 level for the quality element under consideration
Very serious	Issues with the evidence sufficient to downgrade by 2 levels for the quality element under consideration

11 **Table 4: Overall quality of the evidence in GRADE (by outcome)**

Overall quality grading	Description
High	Further research is very unlikely to change the level of confidence in the estimate of effect
Moderate	Further research is likely to have an important impact on the level of confidence in the estimate of effect and may change the estimate
Low	Further research is very likely to have an important impact on the level of confidence in the estimate of effect and is likely to change the estimate
Very low	The estimate of effect is very uncertain

## 1 *Assessing risk of bias in intervention reviews*

2 Bias is a systematic error, or consistent deviation from the truth in results obtained.  
3 When a risk of bias is present the true effect can be either under- or over-estimated.

4 Risk of bias in RCTs was assessed using the Cochrane risk of bias tool version 2  
5 (see Appendix H in Developing NICE guidelines: the manual).

6 The Cochrane risk of bias tool assesses the following possible sources of bias:

- 7 • risk of bias arising from the randomization process
- 8 • risk of bias due to deviations from the intended interventions
- 9 • risk of bias due to missing outcome data
- 10 • risk of bias due to measurement of the outcome
- 11 • risk of bias in selection of the reported result

12 A study with a poor methodological design does not automatically imply high risk of  
13 bias; the bias is considered individually for each outcome and it is assessed whether  
14 the chosen design and methodology will impact on the estimation of the intervention  
15 effect.

16 More details about version 2 of the Cochrane risk of bias tool can be found in Section  
17 8 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).

18 For systematic reviews the ROBIS checklist was used (see Appendix H in  
19 Developing NICE guidelines: the manual)

20 For non-randomised studies the ROBINS-I checklist was used (see Appendix H in  
21 Developing NICE guidelines: the manual).

## 22 *Assessing inconsistency in intervention reviews*

23 Inconsistency refers to unexplained heterogeneity in results of meta-analysis. When  
24 estimates of treatment effect vary widely across studies (that is, there is  
25 heterogeneity or variability in results), this suggests true differences in underlying  
26 effects. Inconsistency is, thus, only truly applicable when statistical meta-analysis is  
27 conducted (that is, results from different studies are pooled). When outcomes were  
28 derived from a single study the rating 'no serious inconsistency' was used when  
29 assessing this domain, as per GRADE methodology (Santesso 2016).

30 Inconsistency was assessed visually by inspecting forest plots and observing  
31 whether there was considerable heterogeneity in the results of the meta-analysis (for  
32 example if the point estimates of the individual studies consistently showed benefits  
33 or harms). This was supported by calculating the I-squared statistic for the meta-  
34 analysis with an I-squared value of more than 50% indicating serious heterogeneity,  
35 and more than 80% indicating very serious heterogeneity. When serious or very  
36 serious heterogeneity was observed, possible reasons were explored and subgroup  
37 analyses were performed as pre-specified in the review protocol where possible. In  
38 the case of unexplained heterogeneity, sensitivity analyses were planned based on  
39 the quality of studies, eliminating studies at high risk of bias (in relation to  
40 randomisation, allocation concealment and blinding, and/or missing outcome data).

41 When no plausible explanation for the serious or very serious heterogeneity could be  
42 found, the quality of the evidence was downgraded in GRADE for inconsistency and

1 the meta-analysis was re-run using the Der-Simonian and Laird method with a  
2 random effects model and this was used for the final analysis.

### 3 *Assessing indirectness in intervention reviews*

4 Directness refers to the extent to which populations, interventions, comparisons and  
5 outcomes reported in the evidence are similar to those defined in the inclusion  
6 criteria for the review and was assessed by comparing the PICO elements in the  
7 studies to the PICO defined in the review protocol. Indirectness is important when  
8 such differences are expected to contribute to a difference in effect size, or may  
9 affect the balance of benefits and harms considered for an intervention.

### 10 *Assessing imprecision and importance in intervention reviews*

11 Imprecision in GRADE methodology refers to uncertainty around the effect estimate  
12 and whether or not there is an important difference between interventions (that is,  
13 whether the evidence clearly supports a particular recommendation or appears to be  
14 consistent with several candidate recommendations). Therefore, imprecision differs  
15 from other aspects of evidence quality because it is not concerned with whether the  
16 point estimate is accurate or correct (has internal or external validity). Instead, it is  
17 concerned with uncertainty about what the point estimate actually represents. This  
18 uncertainty is reflected in the width of the CI.

19 The 95% CI is defined as the range of values within which the population value will  
20 fall on 95% of repeated samples, were the procedure to be repeated. The larger the  
21 study, the smaller the 95% CI will be and the more certain the effect estimate.

22 Imprecision was assessed in the guideline evidence reviews by considering whether  
23 the width of the 95% CI of the effect estimate was relevant to decision making,  
24 considering each outcome independently. This is illustrated in Figure 1, which  
25 considers a positive outcome for the comparison of two treatments. Three decision-  
26 making zones can be differentiated, bounded by the thresholds for minimal  
27 importance (minimally important differences; MIDs) for benefit and harm.


28 When the CI of the effect estimate is wholly contained in 1 of the 3 zones there is no  
29 uncertainty about the size and direction of effect, therefore, the effect estimate is  
30 considered precise; that is, there is no imprecision.

31 When the CI crosses 2 zones, it is uncertain in which zone the true value of the effect  
32 estimate lies and therefore there is uncertainty over which decision to make. The CI  
33 is consistent with 2 possible decisions, therefore, the effect estimate is considered to  
34 be imprecise in the GRADE analysis and the evidence is downgraded by 1 level  
35 ('serious imprecision').

36 When the CI crosses all 3 zones, the effect estimate is considered to be very  
37 imprecise because the CI is consistent with 3 possible decisions and there is  
38 therefore a considerable lack of confidence in the results. The evidence is therefore  
39 downgraded by 2 levels in the GRADE analysis ('very serious imprecision').

40 Implicitly, assessing whether a CI is in, or partially in, an important zone, requires the  
41 guideline committee to estimate an MID or to say whether they would make different  
42 decisions for the 2 confidence limits.

1 **Figure 1: Assessment of imprecision and importance in intervention reviews**  
 2 **using GRADE**



3  
 4 *MID, minimally important difference*

#### 5 *Defining minimally important differences for intervention reviews*

6 The committee was asked whether there were any recognised or acceptable MID in  
 7 the published literature and community relevant to the review questions under  
 8 consideration. The committee was not aware of any MID that could be used for the  
 9 guideline.

10 In the absence of published or accepted MID, the committee agreed to use the  
 11 GRADE default MID to assess imprecision. For dichotomous outcomes minimally  
 12 important thresholds for a RR of 0.8 and 1.25 respectively were used as default MID  
 13 in the guideline. The committee also chose to use 0.8 and 1.25 as the MID for ORs  
 14 & HRs in the absence of published or accepted MID. ORs were predominantly used  
 15 in the guideline when Peto OR were indicated due to low event rates, at low event  
 16 rates OR are mathematically similar to RR making the extrapolation appropriate.  
 17 While no default MID exist for HR, the committee agreed for consistency to continue  
 18 to use 0.8 and 1.25 for these outcomes.

19 If risk difference was used for meta-analysis, for example if the majority of studies  
 20 had zero events in either arm, imprecision was assessed based on sample size using  
 21 200 and 400 as cut-offs for very serious and serious imprecision respectively. These  
 22 sample size cut-offs were also used to judge imprecision when results were  
 23 presented as medians. The committee used these numbers based on commonly  
 24 used optimal information size thresholds.

25 The same thresholds were used as default MID in the guideline for all dichotomous  
 26 outcomes considered in intervention evidence reviews. For continuous outcomes  
 27 default MID are equal to half the median SD of the control groups at baseline (or at  
 28 follow-up if the SD is not available a baseline).

#### 29 *Assessing publication bias in intervention reviews*

30 There were no meta-analyses of 3 or more studies in this guideline so funnel plots  
 31 were not produced to assess potential for publication bias and evidence was not  
 32 downgraded for publication bias.



## 1 Qualitative studies

### 2 *GRADE-CERQual methodology for qualitative reviews*

3 For qualitative reviews an adapted GRADE Confidence in the Evidence from  
4 Reviews of Qualitative research (GRADE-CERQual) approach (Lewin 2015) was  
5 used. In this approach the quality of evidence is considered according to themes in  
6 the evidence. The themes may have been identified in the primary studies or they  
7 may have been identified by considering the reports of a number of studies. Quality  
8 elements assessed using GRADE-CERQual are listed and defined in Table 5. Each  
9 element was graded using the levels of concern summarised in Table 6.

10 The ratings for each component were combined (as with other types of evidence) to  
11 obtain an overall assessment of quality for each theme as described in Table 7  
12 Table 7. 'Confidence' in this context refers to the extent to which the review finding is a  
13 reasonable representation of the phenomenon of interest set out in the protocol.  
14 Similar to other types of evidence all review findings start off with 'high confidence'  
15 and are rated down by one or more levels if there are concerns about any of the  
16 individual CERQual components.

17 In line with advice from the CERQual developers, the overall assessment does not  
18 involve numerical scoring for each component but in order to ensure consistency  
19 across and between guidelines, the NGA established some guiding principles for  
20 overall ratings. For example, a review finding would not be downgraded (and  
21 therefore would be assessed with 'high' confidence) if all 4 components had 'no or  
22 very minor' concerns or 3 'no or very minor' and 1 'minor'. At the other extreme, a  
23 review finding would be downgraded 3 times (to 'very low') if at least 2 components  
24 had serious concerns or at least 3 had moderate or serious concerns. A basic  
25 principle was that if any components had serious concerns then overall confidence in  
26 the review finding would be downgraded at least once.

27 Transparency about overall judgements is provided in the CERQual tables, including  
28 a brief reference to components for which there were concerns in the 'level of  
29 concern' column.

30 **Table 5: Adaptation of GRADE quality elements for qualitative reviews**

Quality element	Description
Risk of bias ('Methodological limitations')	Limitations in study design and implementation may bias interpretation of qualitative themes identified. High risk of bias for the majority of the evidence reduces confidence in review findings. Qualitative studies are not usually randomised and therefore would not be downgraded for study design from the outset (they start as high quality)
Relevance (or applicability) of evidence	This refers to the extent to which the evidence supporting the review findings is applicable to the context specified in the review question
Coherence of findings	This refers to the extent to which review findings are well grounded in data from the contributing primary studies and provide a credible explanation for patterns identified in the evidence
Adequacy of data (theme saturation or sufficiency)	This corresponds to a similar concept in primary qualitative research, that is, whether a theoretical point of theme saturation was achieved, at which point no further citations or observations would provide more insight or suggest a different interpretation of the particular theme. It is not equivalent to the number of studies contributing to a theme, but

Quality element	Description
	rather to the depth of evidence and whether sufficient quotations or observations were provided to underpin the findings.

1 **Table 6: CERQual levels of concern (by quality element)**

Level of concern	Definition
None or very minor concerns	Unlikely to reduce confidence in the review finding
Minor concerns	May reduce confidence in the review finding
Moderate concerns	Will probably reduce confidence in the review finding
Serious concerns	Very likely to reduce confidence in the review finding

2 **Table 7: Overall confidence in the evidence in CERQual (by review finding)**

Overall confidence level	Definition
High	It is highly likely that the review finding is a reasonable representation of the phenomenon of interest
Moderate	It is likely that the review finding is a reasonable representation of the phenomenon of interest
Low	It is possible that the review finding is a reasonable representation of the phenomenon of interest
Very low	It is unclear whether the review finding is a reasonable representation of the phenomenon of interest

3 *Assessing methodological limitations in qualitative reviews*

4 Methodological limitations in qualitative studies were assessed using the Critical  
5 Appraisal Skills Programme (CASP) checklist for qualitative studies (see appendix H  
6 in Developing NICE guidelines: the manual). Overall methodological limitations were  
7 derived by assessing the methodological limitations across the 10 areas summarised  
8 in Table 8.

9 **Table 8: Methodological limitations in qualitative studies**

Aims of the research	This domain assesses whether the aims, importance and relevance of the study were described clearly
Appropriateness of using qualitative methodology	This domain assesses whether qualitative research methods were appropriate for investigating the research question, for example, does the study aim to interpret or illuminate actions or subjective experiences
Research design	This domain assesses whether the study approach has been documented clearly and

	if it was justified, for example, based on a theoretical framework
Recruitment strategy	This domain assesses the procedure and reasons for the method of selecting participants and whether reasons for non-participation are discussed
Data collection	This domain assesses the documentation and justification of the method of data collection (in-depth interviews, semi-structured interviews, focus groups or observations). It also assesses where interviews took place, what form the data took (e.g., tape recordings, written notes) and data saturation
Relationship between researcher and participants	This domain assesses who conducted any interviews, any potential biases they might have and how these might have influenced the research questions or data collection. The assessment should include consideration of how the researcher responded to events during the study
Ethical considerations	This domain assesses whether ethical approval was obtained and ethical standards maintained, including issues of informed consent, confidentiality and the effect of the study on participants
Data analysis	This domain assesses whether sufficient detail was documented for the analytical process and whether it was in accordance with the theoretical approach. For example, if a thematic analysis was used, the assessment would focus on the description of the approach used to generate themes. Consideration of whether contradictory data are taken into account and whether the researcher considered their own biases during analysis and selection of data for presentation also forms part of this assessment
Findings	This domain assesses whether findings are credible, reported explicitly and discussed in the context of the original research question. It also assesses if findings for and against the researchers' arguments are discussed
Value of research	This domain assesses if the researchers discuss the generalisability of findings, the contribution they make to existing knowledge and directions for future research

### 1 *Assessing relevance of evidence in qualitative reviews*

- 2 Relevance (applicability) of findings in qualitative research is the equivalent of  
3 indirectness for quantitative outcomes, and refers to how closely the aims and

1 context of studies contributing to a theme reflect the objectives outlined in the  
2 guideline review protocol.

### 3 *Assessing coherence of findings in qualitative reviews*

4 For qualitative research, a similar concept to inconsistency is coherence, which  
5 refers to the way findings within themes are described and whether they make sense.  
6 This concept was used in the quality assessment across studies for individual  
7 themes. This does not mean that contradictory evidence was automatically  
8 downgraded, but that it was highlighted and presented, and that reasoning was  
9 provided. Provided the themes, or components of themes, from individual studies fit  
10 into a theoretical framework, they do not necessarily have to reflect the same  
11 perspective. It should, however, be possible to explain these by differences in context  
12 (for example, the views of healthcare professionals might not be the same as those  
13 of family members, but they could contribute to the same overarching themes).

### 14 *Assessing adequacy of data in qualitative reviews*

15 Adequacy of data corresponds to the depth of evidence and whether sufficient  
16 quotations or observations were provided to underpin the findings. The complexity of  
17 the themes is also taken into account when assessing their adequacy. As noted  
18 above, it is not equivalent to the number of studies contributing to a theme, but rather  
19 to the depth of evidence and whether sufficient quotations or observations were  
20 provided to underpin the findings. Data would be considered thin where there is a  
21 lack of information and it is likely that further observations would provide more  
22 insight, and rich where there is sufficient information so further observations would be  
23 unlikely to suggest a different interpretation.

## 24 **Reviewing economic evidence**

25 A global economic literature search was undertaken to cover all review questions in  
26 the guideline.

27 Titles and abstracts of articles identified through the economic literature searches  
28 were independently assessed for inclusion using the predefined eligibility criteria  
29 listed in Table 9.

### 30 **Table 9: Inclusion and exclusion criteria for systematic reviews of economic** 31 **evaluations**

Inclusion criteria
Intervention or comparators in accordance with the guideline scope
Study population in accordance with the guideline scope
Full economic evaluations (cost-utility, cost effectiveness, cost-benefit or cost-consequence analyses) assessing both costs and outcomes associated with interventions of interest. Cost analyses were also considered for inclusion due to the anticipated lack of economic evidence.
Only studies from Organisation for Economic Co-operation and Development countries were included.
Only studies published from 2000 onwards were included in the review.
Exclusion criteria
Abstracts containing insufficient methodological details.

### Inclusion criteria

Cost-of-illness type studies.

- 1 Once the screening of titles and abstracts was completed, full-text copies of  
2 potentially relevant articles were requested for detailed assessment. Inclusion and  
3 exclusion criteria were applied to articles obtained as full-text copies.
- 4 Details of economic evidence study selection, lists of excluded studies, economic  
5 evidence tables, the results of quality assessment of economic evidence (see below)  
6 and economic evidence profiles are presented in each of the evidence reports.

### 7 Appraising the quality of economic evidence

- 8 The quality of economic evidence was assessed using the economic evaluations  
9 checklist specified in [Developing NICE guidelines: the manual](#). See the evidence  
10 reports for further details.

### 11 Economic modelling

12 The aims of the economic input to the guideline were to inform the guideline  
13 committee of potential economic issues to ensure that recommendations represented  
14 a cost effective use of resources. Economic evaluations aim to integrate data on  
15 benefits with the costs of different options. In addition, the economic input aimed to  
16 identify areas of high resource impact; these are recommendations which (while cost  
17 effective) might have a large impact on commissioners and so need special attention.

18 The guideline committee prioritised the following review questions for economic  
19 modelling where it was thought that economic considerations would be particularly  
20 important in formulating recommendations.

- 21 • What are the most effective commissioning and practice models to deliver joined-  
22 up health, social care and education services for disabled children and young  
23 people with severe complex needs?
- 24 • What are the most effective combined approaches to identifying, assessing and  
25 monitoring the health, social care and education needs (including changing needs)  
26 of disabled children and young people with severe complex needs?
- 27 • What combined commissioning, practice and service delivery models are most  
28 effective in meeting the health, social care and education needs (including  
29 changing and evolving needs) of disabled children and young people with severe  
30 complex needs?
- 31 • What are the most effective approaches for health, social care and education  
32 services to work together to promote inclusion, independence and wellbeing of  
33 disabled children and young people with severe complex needs?

34

35 Original economic modelling was not undertaken for any review questions as there  
36 was insufficient effectiveness and cost data to inform new modelling. The committee  
37 was also of a view that care is very individual in this population and that any costings  
38 would not be generalizable.

39

1 Although, no modelling was undertaken the committee made a qualitative judgement  
2 regarding cost effectiveness by considering expected differences in resource and  
3 cost use between options, alongside effectiveness evidence.

#### 4 **Cost effectiveness criteria**

5 In general, an intervention was considered to be cost effective if any of the following  
6 criteria applied (provided that the estimate was considered plausible):

- 7 • the intervention dominated other relevant strategies (that is, it was both less costly  
8 in terms of resource use and more effective compared with all the other relevant  
9 alternative strategies)
- 10 • the intervention cost less than £20,000 per QALY gained compared with the next  
11 best strategy, however, it was acknowledged that this threshold may not be  
12 suitable for interventions that go beyond NHS and Personal Social Services (PSS)  
13 perspective
- 14 • the intervention provided important benefits at an acceptable additional cost when  
15 compared with the next best strategy.

16 The committee's considerations of cost effectiveness are discussed explicitly under  
17 the heading 'Cost effectiveness and resource use' in the relevant evidence reports.

## 18 **Developing recommendations**

### 19 **Guideline recommendations**

20 Recommendations were drafted on the basis of the committee's interpretation of the  
21 available evidence, taking account of the balance of benefits, harms and costs  
22 between different courses of action. When effectiveness and economic evidence was  
23 of poor quality, conflicting or absent, the committee drafted recommendations based  
24 on their expert opinion. The considerations for making consensus-based  
25 recommendations include the balance between potential benefits and harms, the  
26 economic costs or implications compared with the economic benefits, current  
27 practices, recommendations made in other relevant guidelines, person's preferences  
28 and equality issues.

29 The main considerations specific to each recommendation are outlined under the  
30 heading 'The committee's discussion of the evidence' within each evidence review.

31 For further details refer to Developing NICE guidelines: the manual.

### 32 **Research recommendations**

33 When areas were identified for which evidence was lacking, the committee  
34 considered making recommendations for future research. For further details refer to  
35 [Developing NICE guidelines: the manual](#) and [NICE's Research recommendations  
36 process and methods guide](#).

## 1 **Validation process**

2 This guideline was subject to a 6-week public consultation and feedback process. All  
3 comments received from registered stakeholders were responded to in writing and  
4 posted on the NICE website at publication. For further details refer to Developing  
5 NICE guidelines: the manual.

## 6 **Updating the guideline**

7 Following publication, NICE will undertake a surveillance review to determine  
8 whether the evidence base has progressed sufficiently to consider altering the  
9 guideline recommendations and warrant an update. For further details refer to  
10 Developing NICE guidelines: the manual.

## 11 **Funding**

12 The NGA was commissioned by NICE to develop this guideline.

# References

## 2 Bradburn 2007

3  
4 Bradburn, M. J., Deeks, J. J., Berlin, J. A., & Localio, A. R. Much ado about nothing:  
5 A comparison of the performance of meta-analytical methods with rare events.  
6 *Statistics in Medicine*, 26, 53–77, 2007.

## 7 Dixon-Woods 2005

8 Dixon-Woods M, Agarwal S, Jones D et al. (2005) Synthesising qualitative and  
9 quantitative evidence: a review of possible methods. *Journal of Health Services*  
10 *Research & Policy* 10(1), 45–53

## 11 Hayden 2013

12 Jill A. Hayden, Danielle A. van der Windt, Jennifer L. Cartwright, Pierre Côté, Claire  
13 Bombardier. Assessing Bias in Studies of Prognostic Factors. *Ann Intern Med*.  
14 2013;158:280–286. doi: 10.7326/0003-4819-158-4-201302190-00009

## 15 Higgins 2011

16 Higgins JPT, Green S (editors) (2011) *Cochrane Handbook for Systematic Reviews*  
17 *of Interventions Version 5.1.0 [updated 2019]* The Cochrane Collaboration. Available  
18 from [www.handbook.cochrane.org](http://www.handbook.cochrane.org) (accessed 15 April 2021)

## 19 Lewin 2015

20 Lewin S, Glenton C, Munthe-Kaas H et al. (2015) Using qualitative evidence in  
21 decision making for health and social interventions: an approach to assess  
22 confidence in findings from qualitative evidence syntheses (GRADE-CERQual).  
23 *PLoS Med* 12(10), e1001895

## 24 McGowan 2016

25 McGowan J, Sampson M, Salzwedel DM et al. (2016) [PRESS Peer Review of](#)  
26 [Electronic Search Strategies: 2015 guideline statement](#). *Journal of Clinical*  
27 *Epidemiology* 75: 40–6

## 28 NICE 2018

29 National Institute for Health and Care Excellence (NICE) (2014) NICE Policy on  
30 conflicts of interest (updated 2017). Available from  
31 [https://www.nice.org.uk/Media/Default/About/Who-we-are/Policies-and-](https://www.nice.org.uk/Media/Default/About/Who-we-are/Policies-and-procedures/declaration-of-interests-policy.pdf)  
32 [procedures/declaration-of-interests-policy.pdf](https://www.nice.org.uk/Media/Default/About/Who-we-are/Policies-and-procedures/declaration-of-interests-policy.pdf) (accessed 15 April 2021)

## 33 Santesso 2016

34 Santesso N, Carrasco-Labra A, Langendam M et al. (2016) Improving GRADE  
35 evidence tables part 3: detailed guidance for explanatory footnotes supports creating  
36 and understanding GRADE certainty in the evidence judgments. *Journal of clinical*  
37 *epidemiology* 74, 28-39



1